209 related articles for article (PubMed ID: 24460646)
1. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
[TBL] [Abstract][Full Text] [Related]
2. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.
Bladé J; Lust JA; Kyle RA
J Clin Oncol; 1994 Nov; 12(11):2398-404. PubMed ID: 7964956
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin D multiple myeloma.
Lin TL; Shih LY; Dunn P; Wang PN; Wu JH; Kao MC
Chang Gung Med J; 2000 Aug; 23(8):451-7. PubMed ID: 11039246
[TBL] [Abstract][Full Text] [Related]
5. [Multiple myeloma with D immunoglobulin].
Benchekroun L; Ouzzif Z; Bouabdillah M; Jaouhar N; Aoufir F; Aoufi F; Chabraoui L
Ann Biol Clin (Paris); 2011; 69(5):581-7. PubMed ID: 22008139
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
Chen L; Fan F; Deng J; Xu J; Xu A; Sun C; Hu Y
Ann Hematol; 2019 Apr; 98(4):963-970. PubMed ID: 30610280
[TBL] [Abstract][Full Text] [Related]
7. Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
Chong YP; Kim S; Ko OB; Koo JE; Lee D; Park SH; Park SJ; Lee D; Kim SW; Suh C
J Korean Med Sci; 2008 Oct; 23(5):819-24. PubMed ID: 18955788
[TBL] [Abstract][Full Text] [Related]
8. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
9. IgD multiple myeloma. Review of 133 cases.
Jancelewicz Z; Takatsuki K; Sugai S; Pruzanski W
Arch Intern Med; 1975 Jan; 135(1):87-93. PubMed ID: 1111472
[TBL] [Abstract][Full Text] [Related]
10. IgD myeloma: clinical, biological and laboratory features.
Sinclair D
Clin Lab; 2002; 48(11-12):617-22. PubMed ID: 12465746
[TBL] [Abstract][Full Text] [Related]
11. Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chain disease)--a case report.
Rabrenović V; Mijušković Z; Marjanović S; Rabrenović M; Jovanović D; Antić S; Ignjatović L; Petrović M; Pilcević D
Vojnosanit Pregl; 2015 Feb; 72(2):196-9. PubMed ID: 25831916
[TBL] [Abstract][Full Text] [Related]
12. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.
Bladé J; Kyle RA
Hematol Oncol Clin North Am; 1999 Dec; 13(6):1259-72. PubMed ID: 10626149
[TBL] [Abstract][Full Text] [Related]
13. [Light chain escape followed by leukemic transformation in a patient with IgD myeloma].
Hatsuse M; Fuchida S; Okano A; Murakami S; Shimazaki C
Rinsho Ketsueki; 2015 Jan; 56(1):48-50. PubMed ID: 25745970
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials.
Agbuduwe C; Iqbal G; Cairns D; Menzies T; Dunn J; Gregory W; Kaiser M; Owen R; Pawlyn C; Child JA; Davies F; Morgan GJ; Jackson GH; Drayson MT; Basu S
Blood Adv; 2022 Sep; 6(17):5113-5123. PubMed ID: 35790108
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Morris C; Iacobelli S; Gahrton G; van Biezen A; Drake M; Garderet L; Potter M; Schattenberg AV; Cornelissen JJ; Hamladji RM; Martelli M; Petersen E; Rovira M; Bandini G; Kroger N; de Witte T
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1054-8. PubMed ID: 25708221
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival in a case of high-risk type IgD myeloma; a possibility of effectiveness of interferon-alpha and erythropoietin.
Hiyoshi M; Hashimoto S; Ota T; Nakao T; Takubo T; Tagawa S; Tatsumi N
Haematologia (Budap); 1997; 28(3):177-80. PubMed ID: 9283919
[TBL] [Abstract][Full Text] [Related]
17. Immunodiagnosis of IgD multiple myeloma. A report of 17 cases.
Chernokhvostova EV; Batalova TN; German GP; Andreyeva NE
Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(4):539-52. PubMed ID: 6170548
[TBL] [Abstract][Full Text] [Related]
18. IgD multiple myeloma. A report of three cases.
Martini R; Santini S; Bottari G
Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
[TBL] [Abstract][Full Text] [Related]
19. Unusual myelomas: a review of IgD and IgE variants.
Pandey S; Kyle RA
Oncology (Williston Park); 2013 Aug; 27(8):798-803. PubMed ID: 24133829
[TBL] [Abstract][Full Text] [Related]
20. [Systemic amyloidosis associated with IgD-λ multiple myeloma].
Nagamachi Y; Yamauchi N; Muramatsu H; Inomata H; Nozawa E; Koyama R; Ihara K; Nishisato T; Yamada H; Yano T; Kikuchi S; Hirako T; Kitaoka K; Ono K; Ihara H; Kato J
Rinsho Ketsueki; 2011 Dec; 52(12):1888-92. PubMed ID: 22241157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
